The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior

Bibliography

• Barenholz YC. Doxil(R) - The first FDA-approved nano-drug: lessons learned. J Control Release 2012;160:117-34
   PubMed Web of Science ®Google Scholar
• Fu Q, Sun J, Zhang W, et al. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov 2009;4:262-72
   PubMed Web of Science ®Google Scholar
• Corot C, Robert P, Idee JM, et al. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006;58:1471-504
   PubMed Web of Science ®Google Scholar
• Nel AE, Madler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009;8:543-57
   PubMed Web of Science ®Google Scholar
• Mahmoudi M, Lynch I, Ejtehadi MR, et al. Protein-nanoparticle interactions: opportunities and challenges. Chem Rev 2011;111:5610-37
   PubMed Web of Science ®Google Scholar
• Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv 2011;8:343-57
   PubMed Web of Science ®Google Scholar
• Aggarwal P, Hall JB, McLeland CB, et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009;61:428-37
   PubMed Web of Science ®Google Scholar
• Goppert TM, Muller RH. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm 2005;302:172-86
   PubMed Web of Science ®Google Scholar
• Camner P, Lundborg M, Lastbom L, et al. Experimental and calculated parameters on particle phagocytosis by alveolar macrophages. J Appl Physiol (1985) 2002;92:2608-16
   PubMed Web of Science ®Google Scholar
• Kreuter J, Hekmatara T, Dreis S, et al. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release 2007;118:54-8
   PubMed Web of Science ®Google Scholar
• Michaelis K, Hoffmann MM, Dreis S, et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 2006;317:1246-53
   PubMed Web of Science ®Google Scholar
• Peracchia MT, Harnisch S, Pinto-Alphandary H, et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 1999;20:1269-75
   PubMed Web of Science ®Google Scholar
• Owens DR, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307:93-102
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82
   PubMed Web of Science ®Google Scholar
• Barran-Berdon AL, Pozzi D, Caracciolo G, et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir 2013;29:6485-94
   PubMed Web of Science ®Google Scholar
• Vroman L, Adams AL, Fischer GC, et al. Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. Blood 1980;55:156-9
   PubMed Web of Science ®Google Scholar
• Zhang S, Nelson A, Beales PA. Freezing or wrapping: the role of particle size in the mechanism of nanoparticle–biomembrane interaction. Langmuir 2012;28:12831-7
   PubMed Web of Science ®Google Scholar
• Lacerda SHDP, Park JJ, Meuse C, et al. Interaction of gold nanoparticles with common human blood proteins. ACS Nano 2009;4:365-79
   Web of Science ®Google Scholar
• Tenzer S, Docter D, Rosfa S, et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 2011;5:7155-67
   PubMed Web of Science ®Google Scholar
• Jennings TL, Singh MP, Strouse GF. Fluorescent lifetime quenching near d = 1.5 nm gold nanoparticles: probing NSET validity. J Am Chem Soc 2006;128:5462-7
   PubMed Web of Science ®Google Scholar
• Lindman S, Lynch I, Thulin E, et al. Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. Nano Lett 2007;7:914-20
   PubMed Web of Science ®Google Scholar
• Nagayama S, Ogawara K, Fukuoka Y, et al. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm 2007;342:215-21
   PubMed Web of Science ®Google Scholar
• Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006;6:662-8
   PubMed Web of Science ®Google Scholar
• Mahmoudi M, Shokrgozar MA, Sardari S, et al. Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles. Nanoscale 2011;3:1127-38
   PubMed Web of Science ®Google Scholar
• Caracciolo G, Pozzi D, Capriotti AL, et al. Effect of DOPE and cholesterol on the protein adsorption onto lipid nanoparticles. J Nanopart Res 2013;15:1498
   Google Scholar
• Scopelliti PE, Borgonovo A, Indrieri M, et al. The effect of surface nanometre-scale morphology on protein adsorption. PLoS One 2010;5:e11862
   PubMed Web of Science ®Google Scholar
• Ge C, Du J, Zhao L, et al. Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proc Natl Acad Sci USA 2011;108:16968-73
   PubMed Web of Science ®Google Scholar
• Capriotti AL, Caracciolo G, Cavaliere C, et al. Do plasma proteins distinguish between liposomes of varying charge density? J Proteomics 2012;75:1924-32
   PubMed Web of Science ®Google Scholar
• Treuel L, Malissek M, Grass S, et al. Quantifying the influence of polymer coatings on the serum albumin corona formation around silver and gold nanoparticles. J Nanopart Res 2012;14:1102
   Google Scholar
• Capriotti AL, Caracciolo G, Caruso G, et al. Label-free quantitative analysis for studying the interactions between nanoparticles and plasma proteins. Anal Bioanal Chem 2013;405:635-45
   PubMed Web of Science ®Google Scholar
• Sharma G, Valenta DT, Altman Y, et al. Polymer particle shape independently influences binding and internalization by macrophages. J Control Release 2010;147:408-12
   PubMed Web of Science ®Google Scholar
• Leroueil PR, Hong S, Mecke A, et al. Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face? Acc Chem Res 2007;40:335-42
   PubMed Web of Science ®Google Scholar
• Canton I, Battaglia G. Endocytosis at the nanoscale. Chem Soc Rev 2012;41:2718-39
   PubMed Web of Science ®Google Scholar
• Shah S, Liu Y, Hu W, et al. Modeling particle shape-dependent dynamics in nanomedicine. J Nanosci Nanotechnol 2011;11:919-28
   PubMed Web of Science ®Google Scholar
• Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 2006;103:4930-4
   PubMed Web of Science ®Google Scholar
• Gratton SE, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 2008;105:11613-18
   PubMed Web of Science ®Google Scholar
• Poland CA, Duffin R, Kinloch I, et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 2008;3:423-8
   PubMed Web of Science ®Google Scholar
• Decuzzi P, Godin B, Tanaka T, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release 2010;141:320-7
   PubMed Web of Science ®Google Scholar
• Yi X, Shi X, Gao H. Cellular uptake of elastic nanoparticles. Phys Rev Lett 2011;107:98101
   PubMed Web of Science ®Google Scholar
• Bertrand N, Leroux JC. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release 2012;161:152-63
   PubMed Web of Science ®Google Scholar
• Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19:899-909
   PubMed Web of Science ®Google Scholar
• Sarparanta M, Bimbo LM, Rytkonen J, et al. Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution. Mol Pharm 2012;9:654-63
   PubMed Web of Science ®Google Scholar
• Photos PJ, Bacakova L, Discher B, et al. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 2003;90:323-34
   PubMed Web of Science ®Google Scholar
• Sacchetti C, Motamedchaboki K, Magrini A, et al. Surface polyethylene glycol conformation influences the protein corona of polyethylene glycol-modified single-walled carbon nanotubes: potential implications on biological performance. ACS Nano 2013;7:1974-89
   PubMed Web of Science ®Google Scholar
• Walkey CD, Olsen JB, Guo H, et al. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc 2012;134:2139-47
   PubMed Web of Science ®Google Scholar
• Larson TA, Joshi PP, Sokolov K. Preventing protein adsorption and macrophage uptake of gold nanoparticles via a hydrophobic shield. ACS Nano 2012;6:9182-90
   PubMed Web of Science ®Google Scholar
• Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 2008;354:56-62
   PubMed Web of Science ®Google Scholar
• Ishida T, Maeda R, Ichihara M, et al. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release 2003;88:35-42
   PubMed Web of Science ®Google Scholar
• Hu CM, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA 2011;108:10980-5
   PubMed Web of Science ®Google Scholar
• Huang J, Bu L, Xie J, et al. Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano 2010;4:7151-60
   PubMed Web of Science ®Google Scholar
• Maletinska L, Blakely EA, Bjornstad KA, et al. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 2000;60:2300-3
   PubMed Web of Science ®Google Scholar
• Chen X, Plasencia C, Hou Y, et al. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem 2005;48:1098-106
   PubMed Web of Science ®Google Scholar
• Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009;13:256-62
   PubMed Web of Science ®Google Scholar
• van Sluis R, Bhujwalla ZM, Raghunand N, et al. In vivo imaging of extracellular pH using 1H MRSI. Magn Reson Med 1999;41:743-50
   PubMed Web of Science ®Google Scholar
• Gao H, Pang Z, Jiang X. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm Res 2013;30:2485-98
   PubMed Web of Science ®Google Scholar
• Shi J, Xiao Z, Kamaly N, et al. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res 2011;44:1123-34
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Zhang S, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep 2013;3:2534
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66:6732-40
   PubMed Web of Science ®Google Scholar
• Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 2011;153:198-205
   PubMed Web of Science ®Google Scholar
• Ding HM, Ma YQ. Role of physicochemical properties of coating ligands in receptor-mediated endocytosis of nanoparticles. Biomaterials 2012;33:5798-802
   PubMed Web of Science ®Google Scholar
• Jiang W, Kim BY, Rutka JT, et al. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008;3:145-50
   PubMed Web of Science ®Google Scholar
• Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013;8:137-43
   PubMed Web of Science ®Google Scholar
• Albanese A, Chan WC. Effect of gold nanoparticle aggregation on cell uptake and toxicity. ACS Nano 2011;5:5478-89
   PubMed Web of Science ®Google Scholar
• Pang Z, Lu W, Gao H, et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release 2008;128:120-7
   PubMed Web of Science ®Google Scholar
• Lu W, Wan J, She Z, et al. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release 2007;118:38-53
   PubMed Web of Science ®Google Scholar
• Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364-6
   PubMed Web of Science ®Google Scholar
• Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 2006;103:11838-43
   PubMed Web of Science ®Google Scholar
• Demeule M, Regina A, Che C, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 2008;324:1064-72
   PubMed Web of Science ®Google Scholar
• Li J, Feng L, Fan L, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011;32:4943-50
   PubMed Web of Science ®Google Scholar
• Chen Z, Deng J, Zhao Y, et al. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. Int J Nanomedicine 2012;7:3803-11
   PubMed Web of Science ®Google Scholar
• Kuai R, Yuan W, Qin Y, et al. Efficient delivery of payload into tumor cells in a controlled manner by tat and thiolytic cleavable PEG Co-modified liposomes. Mol Pharm 2010;7(5):1816-26
   PubMedGoogle Scholar
• Kuai R, Yuan W, Li W, et al. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration. Mol Pharm 2011;8:2151-61
   PubMed Web of Science ®Google Scholar
• Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 2008;1786:126-38
   PubMed Web of Science ®Google Scholar
• McNeeley KM, Karathanasis E, Annapragada AV, et al. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 2009;30:3986-95
   PubMed Web of Science ®Google Scholar
• Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release 2007;118:216-24
   PubMed Web of Science ®Google Scholar
• Sethuraman VA, Lee MC, Bae YH. A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm Res 2008;25:657-66
   PubMed Web of Science ®Google Scholar
• Olson ES, Jiang T, Aguilera TA, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci USA 2010;107:4311-16
   PubMed Web of Science ®Google Scholar
• Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 2004;101:17867-72
   PubMed Web of Science ®Google Scholar
• Gu G, Xia H, Hu Q, et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials 2013;34:196-208
   PubMed Web of Science ®Google Scholar